Neuroptix closes $1.6M funding round

Neuroptix Corp., an Acton firm with a focus on Alzheimer's disease, has closed a $1.6 million funding round.

The firm seeks ways to detect signs of Alzheimer's early through non-invasive laser eye scanning, and it said today that it has successfully closed its Series A funding round to help further commercialize its diagnostic platform.

The investment was led by Launchpad Venture Group, a Boston angel-investment firm, Neuroptix said.

Neuroptix's approach to the early detection of Alzheimer's consists of a laser eye-scanning device combined with an eye drop that identifies Alzheimer's related proteins found in the lens of the eye.
(By Chris Reidy, Globe staff)